New findings add to the understanding of the patient experience in axial spondyloarthritis (axSpA), which can help inform ...
Linda Bosserman, MD, PhD, FASCO, FACP, of City of Hope highlights challenges in cancer care, focusing on improving access to ...
The proposed Medicare High-Value Drug List Model, also known as the Medicare $2 Drug List, could have modestly reduced out-of ...
On day 1 of the Family Heart Global Summit, speakers highlighted the critical need for awareness, early diagnosis, and ...
World Dense Breast Day emphasizes the need for awareness and advocacy for individuals with dense breasts, which can ...
New research highlights increased stroke, heart attack, and heart failure risks in cancer survivors, especially those treated ...
"As CMMI continues to test new equity adjustments, it is important that changes be grounded in scientific principles with ...
The FDA has approved FluMist (AstraZeneca) for self-administration by adults up to age 49 years or for caregiver administration for children aged 2 to 17 years, making it the first self-administered ...
Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...
Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & ...
The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.
Experts in cardiometabolic risk management examine the factors contributing to low adherence to guidelines for cardiometabolic conditions, with a specific focus on type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback